Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals (IONS) is a US‑based biotechnology company specialised in antisense oligonucleotide (ASO) therapeutics — short strands of RNA designed to modulate gene expression. With a market capitalisation of about $11.42 billion, Ionis operates a platform-driven model: it advances a pipeline across neurology, cardiometabolic and rare diseases while partnering with larger pharma firms for development, regulatory and commercialisation support. Revenue typically comes from milestone payments, licensing fees and royalties rather than steady product sales, which can make financials lumpy. The company’s science-driven approach offers the potential for targeted medicines where conventional drugs struggle, but the path from early research to approved therapy is lengthy and uncertain. Investors should expect clinical trial binary events, regulatory dependency and periodic volatility. This profile is for educational purposes only and is not investment advice; prospective investors should consider their risk tolerance and seek personalised advice before investing.